Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris

Interleukin 4 inhibition as a potential therapeutic in pemphigus

(2016) Soheil Tavakolpour et al.   CYTOKINE

Interleukin 21 as a new possible player in pemphigus: Is it a suitable target?

(2016) Soheil Tavakolpour   INTERNATIONAL IMMUNOPHARMACOLOGY

Targeted Delivery of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand to Keratinocytes with a Pemphigus mAb

(2013) Michiyoshi Kouno et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

MAPKAP Kinase 2 (MK2)-Dependent and -Independent Models of Blister Formation in Pemphigus Vulgaris

(2013) Xuming Mao et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface

(2012) Giovanni Di Zenzo et al.   JOURNAL OF CLINICAL INVESTIGATION

Epitope Spreading Is Rarely Found in Pemphigus Vulgaris by Large-Scale Longitudinal Study Using Desmoglein 2–Based Swapped Molecules

(2012) Bungo Ohyama et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pathogenic Anti-Desmoglein MAbs Show Variable ELISA Activity because of Preferential Binding of Mature versus Proprotein Isoforms of Desmoglein 3

(2009) Preety M. Sharma et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Mechanism and Regulation of Class Switch Recombination

(2008) Janet Stavnezer et al.   Annual Review of Immunology

Disruption of Desmosome Assembly by Monovalent Human Pemphigus Vulgaris Monoclonal Antibodies

(2008) Xuming Mao et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY